Last C$5.08 CAD
Change Today 0.00 / 0.00%
Volume 0.0
QLT On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GS
As of 3:59 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

qlt inc (QLT) Snapshot

Open
C$5.25
Previous Close
C$5.08
Day High
C$5.25
Day Low
C$5.08
52 Week High
01/30/14 - C$7.90
52 Week Low
10/9/13 - C$4.33
Market Cap
259.5M
Average Volume 10 Days
2.4K
EPS TTM
C$-0.53
Shares Outstanding
51.1M
EX-Date
06/28/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QLT INC (QLT)

qlt inc (QLT) Related Businessweek News

No Related Businessweek News Found

qlt inc (QLT) Details

QLT Inc., a biotechnology company, develops and commercializes ocular products that address the unmet medical needs of patients and clinicians worldwide. It focuses on the development of QLT091001, a synthetic retinoid compound, which is in phase Ib retreatment clinical trials for the treatment of leber congenital amaurosis and retinitis pigmentosa; phase Ib clinical trials for the treatment of Retinitis Pigmentosa with autosomal dominant mutation in RPE65; and phase IIa clinical trials for the treatment of impaired dark adaptation. The company was founded in 1981 and is headquartered in Vancouver, Canada.

37 Employees
Last Reported Date: 08/4/14
Founded in 1981

qlt inc (QLT) Top Compensated Officers

Principal Executive Officer, Independent Dire...
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $233.8K
Compensation as of Fiscal Year 2013.

qlt inc (QLT) Key Developments

QLT Inc. Announces Positive Final Results from Phase 1b Retreatment Trial With Oral Synthetic cis-Retinoid (QLT091001) in Subjects With LCA or RP Due to Mutations in RPE65 or LRAT

QLT Inc. announced positive final results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT). The results, which confirm the top line efficacy and safety outcomes reported from the study in February 2014, will be presented tomorrow, September 13, 2014, at the 47(th) Annual Scientific Meeting of The Retina Society in Philadelphia, PA, by Dr. Hendrik Scholl, the Dr. Frieda Derdeyn Bambas Professor of Ophthalmology and Director of the Visual Neurophysiology Service at the Wilmer Eye Institute at the Johns Hopkins Hospital, and an investigator in the trial. The presentation slides will be made available on QLT's web site following the Retina Society Meeting. This multicenter, open-label Phase 1b retreatment trial was an extension study in which LCA or RP subjects with RPE65 or LRAT mutations who had been treated with a single course of QLT091001 in the Company's previously completed Phase 1b study, received up to three 7-day courses of QLT091001 to assess visual outcomes and safety following retreatment. Subjects received treatment with QLT091001 at doses of 10, 40 or 60 mg/m(2), with the majority of subjects receiving 40 mg/m(2) . Visual fields were assessed using Goldmann visual field (GVF) and visual acuity was assessed using best-corrected visual acuity (BCVA) at baseline and days 7, 14, 30 and 60 after each treatment course, then bimonthly until the next treatment course. Results of the final analysis confirmed the response rates previously reported in February 2014, with 19 of 27 subjects (70%) having a visual field response (increase in retinal area of at least 20% from the study baseline at 2 consecutive visits starting within 6 months of any study treatment), and 19 of 27 subjects (70%) having a visual acuity response (increase of at least 5 letters at 2 consecutive visits starting within 6 months of any study treatment). Over the course of the entire study spanning multiple treatment courses, these responses were durable, with the visual field response lasting an average of 235 days (Min-Max = 7 -- 742 days), and the visual acuity response lasting an average of 232 days (Min-Max = 7 -- 616 days). Overall, 10 of 13 LCA subjects (77%), and 12 of 14 RP subjects (86%) were classified as responders for either visual field retinal area or visual acuity.

QLT Inc., Annual General Meeting, Oct 01, 2014

QLT Inc., Annual General Meeting, Oct 01, 2014.

QLT Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

QLT Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company posted loss per share from continuing operations of $0.17, compared with the prior-year period's $0.12 per share. Increase in loss per share is due to the $2.5 million of consulting and transaction fees incurred in connection with the evaluation of strategic alternatives and the resulting proposed Merger with Auxilium, which was partially offset by lower R&D and restructuring expenses. The company booked a deeper loss of $8.6 million compared to $6.2 million a year ago. Much of the loss came from higher expenses paid for consulting and transaction fees as the company explored its strategic alternatives earlier this year. Operating loss was $8,578,000 against $7,125,000 a year ago. Loss from continuing operations before income taxes was $8,558,000 compared to $5,887,000 a year ago. Loss from continuing operations was $8,581,000 compared to $6,029,000 a year ago. For the six months, the company reported operating loss of $16,349,000 compared to $14,344,000 a year ago. Loss from continuing operations before income taxes was $14,805,000 compared to $12,321,000 a year ago. Loss from continuing operations was $15,043,000 compared to $12,646,000 a year ago. Net loss was $15,100,000 or $0.29 basic and diluted earnings per share compared to $12,626,000 or $0.25 basic and diluted earnings per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QLT:CN C$5.08 CAD 0.00

QLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QLT.
View Industry Companies
 

Industry Analysis

QLT

Industry Average

Valuation QLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QLT INC, please visit www.qltinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.